No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
623 |
4. Check minimum number of eventsNone |
623 |
5. Include endpointsNone |
623 |
6. Filter based on genotype QC (FinnGen only) |
602 |
Control definitions (FinnGen only)
- Control exclude
- L12_DERMATITISECZEMA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L30
- Name in latin
- Pompholyx
Similar endpoints
↥List of similar endpoints to
Dyshidrosis [pompholyx]
based on the number of shared cases.
Similar with more cases:
- Dermatitis
- Dermatitis and eczema
- Diseases of the skin and subcutaneous tissue
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3645 | 2184 | 1440 |
| Only index persons | 3395 | 2092 | 1303 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.06 | 0.04 |
| Only index persons | 0.07 | 0.08 | 0.05 |
| Median age at first event (years) | |||
| Whole population | 39.06 | 39.22 | 38.77 |
| Only index persons | 38.66 | 38.88 | 38.32 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 602 | 418 | 184 |
| Unadjusted period prevalence (%) | 0.13 | 0.15 | 0.08 |
| Median age at first event (years) | 42.57 | 42.59 | 42.53 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 623
- Matched controls
- 6230
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
24.3
317.1
268
188
XQ802
NOMESCO Finland
Epicutan test
159.0
307.7
231
23
L30.1
ICD-10 Finland
Dyshidrosis [pompholyx]
10286.4
307.7
566
7
XQ800
NOMESCO Finland
Prick test
16.6
198.5
191
162
D07AC13
ATC
mometasone; topical
10.5
196.7
397
895
D07AD01
ATC
clobetasol; topical
10.9
193.1
286
449
L20.0
ICD-10 Finland
Besnier prurigo
+∞
191.9
174
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
10.6
186.9
282
451
L30.3
ICD-10 Finland
Infective dermatitis
47.1
177.3
106
27
L20.9
ICD-10 Finland
Atopic dermatitis, unspecified
+∞
175.5
160
*
D07AC01
ATC
betamethasone; topical
8.5
156.3
415
1187
E0000UV, ,
ATC
8.6
145.8
458
1518
D07BC01
ATC
betamethasone and antiseptics; topical
9.2
129.1
190
284
E000001, ,
ATC
5.9
97.4
243
609
D02AE01
ATC
carbamide; topical
10.5
88.7
106
119
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
6.1
77.2
161
336
L30.0
ICD-10 Finland
Nummular dermatitis
17.4
74.5
63
40
TQW80
NOMESCO Finland
Local dermatologic skincare
23.1
71.6
53
25
L30.8
ICD-10 Finland
Other specified dermatitis
17.5
63.1
53
33
69283
ICD-8 Finland
Other eczema and dermatitis, Dysidroticum (pompholyx)
+∞
59.3
56
*
D07CC01
ATC
betamethasone and antibiotics; topical
5.0
59.1
152
376
D07AB02
ATC
hydrocortisone butyrate; topical
3.8
55.6
259
988
L23.0
ICD-10 Finland
Allergic contact dermatitis due to metals
+∞
53.9
51
*
L23.2
ICD-10 Finland
Allergic contact dermatitis due to cosmetics
289.4
53.0
53
*
317
Kela drug reimbursment
Topical pimecrolimus and tacrolimus
+∞
52.9
50
*
D07AB08
ATC
desonide; topical
5.5
52.0
113
240
J30.10
ICD-10 Finland
Allergic rhinitis due to pollen
5.9
46.5
91
175
L20
ICD-10 Finland
Atopic dermatitis
+∞
44.3
42
*
D07CB01
ATC
triamcinolone and antibiotics; topical
12.4
44.3
45
39
L40.3
ICD-10 Finland
Pustulosis palmaris et plantaris
17.3
43.0
36
22
L23.5
ICD-10 Finland
Allergic contact dermatitis due to other chemical products
446.6
42.7
42
*
E000002, ,
ATC
4.6
41.1
111
281
D11AH01
ATC
tacrolimus; topical
412.3
39.5
39
*
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
3.3
37.9
188
721
H02AB06
ATC
prednisolone; systemic
2.9
36.4
346
1891
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
5.7
34.6
69
134
D02AX
ATC
Other emollients and protectives
10.3
34.2
39
40
H02AB04
ATC
methylprednisolone; systemic
3.6
33.6
130
423
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
3.4
30.7
132
458
E000004, ,
ATC
10.8
30.0
33
32
S87
ICPC
Dermatitis/atopic eczema
10.8
30.0
33
32
R06AE07
ATC
cetirizine; oral
2.5
28.7
336
1963
E000007, ,
ATC
5.6
28.4
57
111
69100
ICD-8 Finland
Infantile eczema and related conditions, Eczema atopicum. Prurigo Besnier. Eczema pruriginosum allergicum
+∞
28.3
27
*
D07XC01
ATC
betamethasone; topical
3.6
26.4
97
303
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.3
22.5
61
153
L24.0
ICD-10 Finland
Irritant contact dermatitis due to detergents
+∞
22.0
21
*
R06AE09
ATC
levocetirizine; oral
2.8
21.8
130
537
Z03.8
ICD-10 Finland
Observation for other suspected diseases and conditions
5.0
21.6
48
102
L25.9
ICD-10 Finland
Unspecified contact dermatitis, unspecified cause
52.0
21.3
25
5
E000003, ,
ATC
5.3
21.2
44
88
D09AB01
ATC
zinc bandage without supplements; topical
31.3
20.7
27
9
L23.8
ICD-10 Finland
Allergic contact dermatitis due to other agents
+∞
19.9
19
*
WQ021, ,
NOMESCO Finland
+∞
19.9
19
*
SPAT1263
SPAT
Sampling
2.2
19.8
298
1848
J01DB01
ATC
cefalexin; oral
3.0
19.2
549
4417
NH3BA
NOMESCO Finland
Foot and toes extensive X-ray examination
5.1
18.8
40
82
B35.3
ICD-10 Finland
Tinea pedis
4.7
18.5
44
99
A46
ICD-10 Finland
Erysipelas
2.9
18.2
93
352
R06AX27
ATC
desloratadine; oral
2.2
18.1
228
1307
WQ007, ,
NOMESCO Finland
+∞
17.8
17
*
N05BB01
ATC
hydroxyzine; systemic
3.8
17.5
56
158
S88
ICPC
Dermatitis contact/allergic
7.3
17.5
26
37
D07BA04
ATC
hydrocortisone and antiseptics; topical
3.2
17.3
74
252
ND1BA
NOMESCO Finland
Wrist extensive X-ray examination
5.5
17.2
34
65
D07XB05
ATC
dexamethasone; topical
6.2
16.6
29
49
D05BB02
ATC
acitretin; oral
7.5
16.6
24
33
R06AX22
ATC
ebastine; oral
2.4
16.5
135
644
H25.8
ICD-10 Finland
Other senile cataract
3.8
16.4
52
146
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
2.8
16.1
89
350
Z75.1
ICD-10 Finland
Person awaiting admission to adequate facility elsewhere
6.1
15.8
28
48
SPAT1310
SPAT
Counselling related to known health issue
2.1
15.8
225
1338
L23.1
ICD-10 Finland
Allergic contact dermatitis due to adhesives
87.3
15.6
17
*
H02AB07
ATC
prednisone; oral
2.7
15.4
91
370
N03AX16
ATC
[U] pregabalin
2.2
15.2
151
779
E000006, ,
ATC
3.7
14.7
48
137
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.3
14.7
39
96
L04AX03
ATC
methotrexate; systemic
2.7
14.2
80
317
D07AA02
ATC
hydrocortisone; topical
2.5
14.0
97
426
S76
ICPC
Skin infection other
3.7
13.9
46
133
L23
ICD-10 Finland
Allergic contact dermatitis
20.6
13.9
20
10
T78.4
ICD-10 Finland
Allergy, unspecified
3.7
13.8
44
124
J01AA04
ATC
lymecycline; systemic
2.3
13.7
113
537
R03AC02
ATC
salbutamol; inhalant
1.9
13.7
367
2669
WQ020, ,
NOMESCO Finland
+∞
13.6
13
*
L24.8
ICD-10 Finland
Irritant contact dermatitis due to other agents
143.0
13.5
14
*
ZXX03
NOMESCO Finland
Extent of procedure, 3 units
26.4
13.4
18
7
Z01.2
ICD-10 Finland
Dental examination
1.9
13.1
318
2230
F17.29
ICD-10 Finland
Addiction caused by tobacco UNS
5.8
13.0
24
43
ZXX04
NOMESCO Finland
Extent of procedure, 4 units
32.8
12.6
16
5
69282
ICD-8 Finland
Other eczema and dermatitis, E microbis
+∞
12.5
12
*
WXQ12
NOMESCO Finland
Psoralen - Ultraviolet A therapy with local sensitivisation
132.6
12.5
13
*
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.2
12.4
127
659
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.8
12.3
288
1983
UJF30
NOMESCO Finland
Ileoscopy through colon
2.6
12.2
74
304
J01DA01
ATC
[U] cefalexin
1.8
11.9
389
2956
D07CA01
ATC
hydrocortisone and antibiotics; topical
2.4
11.8
92
426
Z04.3
ICD-10 Finland
Examination and observation following other accident
4.9
11.8
26
55
L20.8
ICD-10 Finland
Other atopic dermatitis
+∞
11.5
11
*
J01MA12
ATC
levofloxacin; systemic
2.2
11.5
107
534
ZXX01
NOMESCO Finland
Extent of proceudre, 1 unit
15.4
11.4
18
12
R03BA05
ATC
fluticasone; inhalant
2.1
11.3
129
696
G47.3
ICD-10 Finland
Sleep apnoea
2.0
11.2
142
796
D07AC14
ATC
methylprednisolone aceponate; topical
3.7
11.2
36
102
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.0
11.1
159
930
R01AD09
ATC
mometasone; nasal
1.8
11.0
308
2216
L01
ICPC
Neck symptom/complaint
2.1
10.9
114
595
L03
ICPC
Low back symptom/complaint
1.9
10.9
183
1128
R01AD08
ATC
fluticasone; nasal
1.8
10.8
200
1270
J01FF01
ATC
clindamycin; systemic
1.9
10.8
168
1009
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.3
10.6
85
397
A02BC02
ATC
pantoprazole; systemic
1.8
10.6
390
3020
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
14.5
10.5
17
12
J20
ICD-10 Finland
Acute bronchitis
2.4
10.5
75
333
L40.0
ICD-10 Finland
Psoriasis vulgaris
4.0
10.5
30
78
D11AX14
ATC
[U] tacrolimus
+∞
10.4
10
*
L12
ICPC
Hand/finger symptom/complaint
2.1
10.4
118
634
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
10.4
244
1661
CS494
NOMESCO Finland
Other visual field testing
5.1
10.1
21
42
XQ848
NOMESCO Finland
Dermatological photography
5.3
9.9
20
39
XG410
NOMESCO Finland
Flow-volume spirometry
3.8
9.8
30
82
B86
ICD-10 Finland
Scabies
4.0
9.8
28
73
GD1AD
NOMESCO Finland
Thorax CT examination
3.3
9.6
36
113
S21
ICPC
Skin texture symptom/complaint
2.2
9.5
91
457
S06
ICPC
Rash localized
3.1
9.5
41
140
M03BX02
ATC
tizanidine; oral
1.7
9.5
396
3132
J01DA09
ATC
[U] cefadroxil
1.8
9.5
173
1088
L28.0
ICD-10 Finland
Lichen simplex chronicus
101.5
9.4
10
*
SPAT1312
SPAT
General health counselling
1.8
9.4
211
1409
L23.9
ICD-10 Finland
Allergic contact dermatitis, unspecified cause
22.1
9.4
13
6
L08.0
ICD-10 Finland
Pyoderma
22.1
9.4
13
6
SPAT1311
SPAT
Counselling and guidance related to occupational health
3.4
9.3
34
105
M01AE02
ATC
naproxen; oral, rectal
1.7
9.2
376
2945
Z2221
NOMESCO Finland
Medical doctor
0.4
9.2
51
1124
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
1.7
9.1
266
1904
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
3.2
9.1
36
117
L23.3
ICD-10 Finland
Allergic contact dermatitis due to drugs in contact with skin
37.3
9.0
11
*
J45.9
ICD-10 Finland
Asthma, unspecified
2.0
8.9
113
631
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.7
8.9
344
2648
Z00.0
ICD-10 Finland
General medical examination
1.9
8.8
123
708
S29
ICPC
Skin symptom/complaint other
2.0
8.8
113
633
Z01.6
ICD-10 Finland
Radiological examination, not elsewhere classified
2.2
8.8
76
367
L24.9
ICD-10 Finland
Irritant contact dermatitis, unspecified cause
50.7
8.7
10
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.2
8.6
79
390
SPAT1283
SPAT
Restricted health certificate
1.8
8.6
146
895
M54.4
ICD-10 Finland
Lumbago with sciatica
1.9
8.5
122
709
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.8
8.5
165
1053
PH2DE
NOMESCO Finland
Ultrasound examination of bloodflow in veins of lower extremity with Doppler method
3.8
8.4
25
67
SPAT1149
SPAT
Suture or treatment of traumatic wound
2.3
8.4
68
319
6918B
ICD-9 Finland
Atopic dermatitis and related conditions, Other atopic dermatitis and related conditions[ECZEMA ATOPICUM]
+∞
8.3
8
*
N02AX02
ATC
tramadol; systemic, rectal
1.7
8.3
235
1658
DFF59
NOMESCO Finland
Other assessment of balance
10.9
8.3
15
14
L50.0
ICD-10 Finland
Allergic urticaria
4.2
8.3
22
54
L98.9
ICD-10 Finland
Disorder of skin and subcutaneous tissue, unspecified
7.2
8.3
19
27
WX100
NOMESCO Finland
Conjunctival surface anesthesia
2.5
8.3
54
230
R06.0
ICD-10 Finland
Dyspnoea
1.8
8.2
141
865
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
1.7
8.2
168
1087
L16
ICPC
Ankle symptom/complaint
2.1
8.1
80
406
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
1.9
8.1
115
666
E0001A1, ,
ATC
3.9
8.0
23
60
SPAT1322
SPAT
Pre-employment physical examination
3.9
8.0
23
60
SPAT1216
SPAT
Assessment of functional ability
2.1
7.9
76
382
L13
ICPC
Hip symptom/complaint
2.0
7.8
99
550
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
2.8
7.8
39
145
JFA15
NOMESCO Finland
Endoscopic polypectomy in colon
2.9
7.8
37
134
K58.0
ICD-10 Finland
Irritable bowel syndrome with diarrhoea
2.6
7.8
44
175
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
2.7
7.7
41
158
D82
ICPC
Teeth/gum disease
1.6
7.6
254
1859
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.2
7.6
64
306
S01GX01
ATC
cromoglicic acid; ophthalmic
1.8
7.5
133
822
ZXX02
NOMESCO Finland
Extent of procedure, 2 units
7.3
7.5
17
24
J01.0
ICD-10 Finland
Acute maxillary sinusitis
1.7
7.4
172
1146
SPAT1260
SPAT
Consultation of another employee
1.9
7.4
103
590
D11AH04
ATC
alitretinoin; oral
81.0
7.4
8
*
L27.2
ICD-10 Finland
Dermatitis due to ingested food
81.0
7.4
8
*
PA7BD
NOMESCO Finland
CT angiography of neck and brain
7.8
7.4
16
21
69299
ICD-8 Finland
Other eczema and dermatitis, Due to other and unspecified cause
+∞
7.3
7
*
J02AC02
ATC
itraconazole; systemic
1.9
7.3
106
617
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
2.7
7.3
38
145
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
2.1
7.2
68
339
NG1BA
NOMESCO Finland
Knee extensive X-ray examination
3.8
7.1
21
56
JN1BG
NOMESCO Finland
MRI examination of upper part of abodmen with high intensity magnet
8.9
7.1
14
16
Z01.8
ICD-10 Finland
Other specified special examinations
1.8
7.1
128
796
J01AA02
ATC
doxycycline; systemic
1.6
7.1
446
3773
C01CA24
ATC
epinephrine; parenteral
2.4
7.1
49
215
L11
ICPC
Wrist symptom/complaint
2.1
7.0
66
329
EB1VA, ,
NOMESCO Finland
1.9
7.0
88
488
D05AX52
ATC
calcipotriol, combinations; topical
2.8
7.0
34
125
M77.0
ICD-10 Finland
Medial epicondylitis
3.4
6.9
24
72
M79.1
ICD-10 Finland
Myalgia
1.9
6.8
99
576
D01BA02
ATC
terbinafine; oral
1.7
6.8
134
854
SPAT1229
SPAT
Assessment of need for aid
2.7
6.8
35
133
D05AX02
ATC
calcipotriol; topical
3.5
6.8
23
68
M75
ICD-10 Finland
Shoulder lesions
2.9
6.7
32
116
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
1.9
6.7
90
509
NB1BG
NOMESCO Finland
Shoulder and humerus MRI examination with high intensity magnet
4.1
6.7
18
45
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic
1.7
6.6
161
1083
SPAT1153
SPAT
Removal of sutures
1.6
6.6
166
1126
SPAT1295
SPAT
Other function in accordance with physical therapy nomenclature
2.8
6.6
33
123
L04AD01
ATC
ciclosporin; systemic
5.4
6.5
18
34
L28.1
ICD-10 Finland
Prurigo nodularis
70.5
6.4
7
*
SPAT1254
SPAT
Administration of medicine
1.9
6.4
81
449
K21.0
ICD-10 Finland
Gastro-oesophageal reflux disease with oesophagitis
2.1
6.4
57
279
J37.0
ICD-10 Finland
Chronic laryngitis
3.0
6.3
27
92
M03BC01
ATC
orphenadrine (citrate); systemic
1.7
6.3
147
976
J01FA10
ATC
azithromycin; systemic
1.5
6.3
378
3116
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
1.9
6.3
81
452
SDE03
NOMESCO Finland
Periodontal treatment by dental hygienist, extensive
1.6
6.3
151
1012
L25.8
ICD-10 Finland
Unspecified contact dermatitis due to other agents
+∞
6.3
6
*
XQ817, ,
NOMESCO Finland
+∞
6.3
6
*
D11AH02
ATC
pimecrolimus; topical
+∞
6.3
6
*
WQ055, ,
NOMESCO Finland
+∞
6.3
6
*
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
1.5
6.3
344
2782
WX722
NOMESCO Finland
PEEP
3.0
6.2
27
93
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.6
6.2
217
1589
R06AX18
ATC
acrivastine; oral
3.4
6.2
22
67
R06AX13
ATC
loratadine; oral
1.8
6.2
102
616
M54.5
ICD-10 Finland
Low back pain
1.6
6.1
215
1575
K13.78
ICD-10 Finland
Other change in the oral mucosa
3.8
6.1
18
48
M50.3
ICD-10 Finland
Other cervical disc degeneration
4.2
6.1
16
39
XG480
NOMESCO Finland
Histamine provocation of respiratroy tract
4.2
6.1
16
39
SPAT1249
SPAT
Treatment-related counselling outside office
1.5
6.1
234
1748
XQ899
NOMESCO Finland
Other assessment of skin
12.7
6.1
10
8
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
6.8
6.1
14
21
N02BE01
ATC
paracetamol; systemic, rectal
1.8
6.0
533
4790
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
245
558
6.59
110.46
4.0
3.8
31.02
31.33
%
0.16
187
383
154
308
6.31
77.19
1.3
1.2
349.66
156.60
u/ml
2.33
145
283
81
159
5.71
40.30
2.0
1.8
—
—
—
0
0
74
147
5.58
36.25
1.9
1.7
—
—
—
0
0
71
158
4.94
30.47
1.2
1.1
3.58
4.51
u/ml
—
6
30
38
45
8.93
29.91
1.6
2.0
21.38
23.53
mg/l
—
8
10
90
246
4.11
29.74
3.8
2.9
5.16
5.12
kpa
0.19
84
238
86
234
4.10
28.56
3.9
2.9
0.81
1.65
mmol/l
0.88
65
165
227
1126
2.60
27.06
2.3
2.0
—
—
—
0
0
44
71
6.59
26.51
1.7
1.3
—
—
—
0
0
44
71
6.59
26.51
1.7
1.3
—
—
—
0
0
43
70
6.52
25.68
1.7
1.3
—
—
—
0
0
43
72
6.34
24.99
1.7
1.3
—
—
—
0
0
43
72
6.34
24.99
1.7
1.3
—
—
—
0
0
43
72
6.34
24.99
1.7
1.3
—
—
—
0
0
30
37
8.47
22.80
1.4
1.2
—
—
—
0
0
364
2394
2.25
21.36
7.0
5.8
29.56
29.25
%
0.23
343
2263
358
2366
2.21
20.40
6.8
5.5
55.84
56.54
%
0.57
338
2235
475
3631
2.30
17.40
4.0
2.9
53.47
43.11
u/l
0.78
442
3434
217
1262
2.10
16.28
1.4
1.3
0.99
1.86
u/ml
1.05
34
338
44
111
4.19
16.02
1.9
1.3
—
—
—
0
0
137
679
2.30
15.21
1.7
1.7
817.84
1172.32
nmol/l
6.32
96
516
114
525
2.43
14.93
4.1
5.6
—
—
—
0
0
43
114
3.98
14.65
1.3
1.4
26.04
18.83
u/l
0.67
34
93
279
1838
1.94
14.30
9.3
9.3
1.23
1.13
inr
0.72
60
575
21
12
18.06
13.91
1.6
1.1
8.34
7.87
ug/l
0.18
21
12
25
26
9.97
12.83
2.8
2.7
44824.00
42396.35
ug/l
0.15
25
26
22
18
12.62
12.69
1.0
1.0
9.68
8.52
u/ml
0.10
15
13
381
2847
1.87
12.63
8.8
8.5
4.11
3.99
e9/l
0.53
352
2502
40
113
3.71
12.47
1.2
1.2
3.20
3.15
u/ml
—
5
14
40
114
3.68
12.31
1.2
1.2
7.12
10.54
u/ml
—
8
21
459
3670
1.95
12.02
4.6
3.7
10.48
9.95
mm/h
0.45
414
3412
219
1425
1.83
10.96
3.4
2.4
55.49
55.56
u/l
0.01
201
1316
250
1698
1.79
10.82
1.9
1.8
106.91
96.91
pmol/l
2.08
146
900
235
1579
1.78
10.47
3.4
3.0
42.51
27.89
ng/l
0.35
141
924
14
6
23.82
10.28
1.4
1.0
—
—
—
0
0
450
3666
1.82
9.99
7.7
6.9
79.09
75.46
u/l
0.69
422
3436
268
1904
1.72
9.60
5.7
5.1
1.23
1.22
mmol/l
1.24
222
1732
41
141
3.04
9.42
1.3
1.8
—
—
—
0
0
124
705
1.95
9.26
2.3
2.4
252.92
111.73
ug/g
0.93
90
552
547
4801
2.14
9.04
5.6
4.6
7.09
2.06
mu/l
0.46
489
4460
313
2367
1.65
8.52
6.3
5.8
9.64
10.63
umol/l
0.97
289
2228
33
107
3.20
8.37
2.9
2.9
—
—
—
0
0
158
1001
1.77
8.29
2.8
2.9
1389.40
859.94
ng/l
0.44
116
823
110
625
1.92
8.17
1.9
1.8
—
—
—
0
0
186
1273
1.66
7.24
2.0
2.0
199.21
215.55
u/l
0.08
179
1207
472
4049
1.68
7.09
4.5
3.9
14.63
14.47
pmol/l
0.79
417
3711
117
718
1.78
6.73
1.6
1.8
1.51
1.42
%
0.62
99
659
20
54
3.79
6.68
1.0
1.1
—
—
—
0
0
339
2709
1.55
6.68
4.1
3.9
6.42
6.49
mmol/l
0.29
311
2474
81
1370
0.53
6.67
2.3
3.3
0.00
0.01
estimate
0.88
18
490
164
1111
1.65
6.56
2.0
2.0
2.88
2.83
mg/l
0.07
131
945
28
96
3.01
6.50
1.1
1.0
2.31
1.62
u/ml
0.39
14
48
277
2129
1.54
6.44
7.4
6.0
1.23
1.22
mmol/l
1.53
239
1803
569
5199
2.09
6.42
14.2
10.9
21.41
20.83
mg/l
0.13
470
3978
23
71
3.33
6.34
1.0
1.0
0.30
0.11
u/ml
—
10
13
25
84
3.06
6.02
1.1
1.0
4.48
3.43
u/ml
0.19
14
31
181
1282
1.58
5.95
1.7
1.6
—
—
—
0
0
70
1199
0.53
5.92
3.1
2.7
0.24
0.43
e6/l
0.91
47
883
27
97
2.86
5.80
1.0
1.1
0.72
1.10
u/ml
0.38
17
40
16
42
3.88
5.57
1.6
2.1
—
—
—
0
0
15
28
5.46
5.56
2.1
1.6
—
—
—
0
0
502
4475
1.63
5.42
6.2
4.9
38.69
38.74
mmol/mol
0.05
447
4190
262
2047
1.48
5.35
2.4
2.2
75.87
74.15
nmol/l
0.38
226
1867
162
1146
1.56
5.28
2.5
2.4
2372.70
6307.25
umol/l
0.94
133
1017
537
4884
1.72
5.20
5.0
3.9
5.81
5.79
mmol/l
0.16
467
4507
194
2515
0.67
5.07
3.9
4.3
0.00
0.00
estimate
0.50
20
493
12
20
6.10
4.93
1.7
2.2
—
—
—
0
0
12
20
6.10
4.93
1.7
2.2
—
—
—
0
0
138
956
1.57
4.90
1.5
1.4
18.39
20.54
nmol/l
1.19
108
815
199
2546
0.68
4.75
2.7
3.1
0.00
0.01
estimate
0.50
18
482
145
1973
0.65
4.72
2.5
3.2
—
—
—
0
0
532
4861
1.65
4.63
4.4
3.5
1.38
1.26
mmol/l
2.47
468
4534
292
2377
1.43
4.59
2.6
2.4
—
—
—
0
0
9
11
8.28
4.57
1.1
1.0
—
—
—
0
0
128
885
1.56
4.56
1.4
1.2
7.36
10.48
u/ml
0.30
39
359
197
2509
0.69
4.51
2.5
3.1
0.00
0.00
estimate
0.50
20
515
131
915
1.55
4.45
1.4
1.3
23.69
29.41
iu/ml
0.32
40
297
15
37
4.13
4.43
1.6
2.2
—
—
—
0
0
586
5523
2.03
4.33
12.2
8.9
27.35
26.60
u/l
0.51
562
5343
50
270
1.93
4.32
2.3
1.6
—
—
—
0
0
36
174
2.13
4.20
1.7
1.7
—
—
—
0
0
547
5067
1.65
4.10
4.7
3.9
4.73
4.75
mmol/l
0.20
488
4772
553
5150
1.66
3.89
14.4
11.7
139.57
139.69
mmol/l
0.50
535
5005
14
44
3.23
3.79
1.0
1.1
—
—
—
0
0
11
24
4.65
3.76
2.5
1.2
—
—
—
0
0
11
24
4.65
3.76
2.5
1.2
—
—
—
0
0
135
982
1.48
3.75
2.9
2.1
—
—
—
0
0
39
205
1.96
3.67
1.5
1.6
—
—
—
0
0
9
16
5.69
3.67
1.8
1.7
—
—
—
0
0
13
35
3.77
3.61
1.5
1.4
1.94
1.94
mmol/l
0.00
13
35
553
5171
1.62
3.56
14.7
11.8
3.95
3.94
mmol/l
0.79
534
5018
6
212
0.28
3.56
1.8
1.7
—
—
—
0
0
11
26
4.29
3.52
2.5
1.2
—
—
—
0
0
11
26
4.29
3.52
2.5
1.2
—
—
—
0
0
12
31
3.93
3.50
1.7
2.1
—
—
—
0
0
12
31
3.93
3.50
1.7
2.1
—
—
—
0
0
12
31
3.93
3.50
1.7
2.1
—
—
—
0
0
549
5129
1.59
3.50
4.7
4.2
2.83
2.85
mmol/l
0.23
484
4801
39
678
0.55
3.37
2.9
2.5
1.83
2.90
e6/l
0.64
17
354
70
451
1.62
3.35
2.0
1.9
384.53
366.25
nmol/l
0.40
62
419
541
5051
1.54
3.31
4.8
3.8
1.44
1.49
mmol/l
1.80
481
4736
26
123
2.16
3.24
1.6
1.3
197.92
341.64
ug/g
2.43
13
68
17
68
2.54
3.06
1.2
1.2
—
—
—
0
0
8
16
5.05
3.06
1.9
2.4
—
—
—
0
0
8
16
5.05
3.06
1.9
2.4
—
—
—
0
0
8
16
5.05
3.06
1.9
2.4
—
—
—
0
0
7
12
5.88
3.02
1.0
1.4
—
—
—
0
0
7
12
5.88
3.02
3.6
2.0
—
—
—
0
0
522
4865
1.45
2.95
11.1
9.8
89.39
88.60
ml/min/173m2
0.34
439
3938
6
9
6.72
2.87
1.0
1.1
—
—
—
0
0
6
189
0.31
2.85
2.3
1.3
—
—
—
0
0
6
189
0.31
2.85
1.5
1.5
—
—
—
0
0
59
381
1.61
2.82
2.3
2.2
0.22
0.22
g/l
0.20
53
363
44
704
0.60
2.81
2.7
2.3
0.72
0.98
e6/l
0.51
22
380
216
1782
1.32
2.76
4.3
4.6
36.22
36.41
g/l
0.18
186
1683
5
6
8.39
2.75
1.2
1.5
—
—
—
0
0
5
6
8.39
2.75
1.2
1.8
—
—
—
0
0
25
125
2.04
2.74
1.1
1.1
1.74
3.54
u/ml
0.57
12
60
6
10
6.05
2.70
1.0
1.1
-1.82
3.62
mmol/l
—
6
10
54
345
1.62
2.70
2.9
2.2
1548.14
4052.10
u/l
0.92
21
152
18
79
2.32
2.70
1.6
1.6
—
—
—
0
0
138
1071
1.37
2.63
3.0
2.2
—
—
—
0
0
5
7
7.19
2.55
1.2
1.0
—
—
—
0
0
5
7
7.19
2.55
1.2
1.0
—
—
—
0
0
116
879
1.39
2.55
1.4
1.6
437.93
38933764.07
pmol/l
1.34
92
750
609
5923
2.25
2.46
21.4
16.3
4.51
4.54
e12/l
0.70
601
5790
52
339
1.58
2.41
2.5
3.5
4.55
4.64
pmol/l
0.28
43
304
6
12
5.04
2.40
1.3
1.4
—
—
—
0
0
9
27
3.37
2.40
8.8
2.5
798.89
567.32
e6/l
—
9
22
609
5927
2.22
2.38
21.5
16.3
136.18
136.15
g/l
0.02
602
5856
125
1579
0.74
2.37
3.4
2.8
—
—
—
0
0
608
5915
2.16
2.35
21.3
16.2
40.18
40.46
%
0.49
583
5606
10
245
0.40
2.31
1.5
1.6
—
—
—
0
0
50
327
1.58
2.30
1.1
1.0
—
—
—
0
0
608
5918
2.14
2.30
21.5
16.3
265.23
256.16
e9/l
2.92
600
5792
170
1388
1.31
2.28
3.6
3.1
7.17
8.04
mmol/l
1.69
129
1191
5
9
5.59
2.21
1.0
1.0
—
—
—
0
0
435
4005
1.29
2.18
3.3
3.4
—
—
—
0
0
87
1141
0.72
2.09
1.6
1.5
—
—
—
0
0
86
1128
0.72
2.06
2.5
3.2
1.02
1.02
kg/l
0.09
23
150
150
1227
1.29
1.97
4.6
3.8
10.85
8.76
mg/mmol
0.22
90
773
26
432
0.58
1.96
2.1
1.8
—
—
—
0
0
26
432
0.58
1.96
3.4
2.9
—
—
—
0
0
5
11
4.57
1.94
1.2
1.2
—
—
—
0
0
5
11
4.57
1.94
1.2
1.3
—
—
—
0
0
42
281
1.53
1.79
1.7
2.2
4.01
7.78
ug/l
1.65
31
249
59
424
1.43
1.78
5.3
3.8
239.31
264.21
u/l
0.34
54
404
15
74
2.05
1.76
1.9
1.8
—
—
—
0
0
15
74
2.05
1.76
1.9
1.8
—
—
—
0
0
175
1481
1.25
1.73
2.2
3.2
2.35
2.35
mmol/l
0.04
129
1326
46
317
1.49
1.72
3.6
3.7
68.03
74.15
ng/l
0.24
39
280
5
13
3.87
1.72
1.4
1.3
—
—
—
0
0
5
13
3.87
1.72
1.4
1.2
—
—
—
0
0
100
1249
0.76
1.71
1.9
1.6
1.64
1.40
mmol/l
1.50
92
1053
0
48
0.00
1.70
0.0
1.3
—
—
—
0
0
38
253
1.53
1.67
1.4
1.5
—
—
—
0
0
35
517
0.66
1.63
2.3
1.9
—
—
—
0
0
26
159
1.66
1.61
1.3
1.3
—
—
—
0
0
16
84
1.93
1.61
1.1
1.1
28.13
145.65
iu/ml
—
8
23
6
20
3.02
1.58
1.0
1.2
1228.67
1370.20
miu/ml
—
6
20
47
651
0.70
1.57
2.4
2.0
—
—
—
0
0
24
146
1.67
1.53
1.6
2.0
1.68
1.38
g/l
0.67
19
126
19
108
1.78
1.52
1.0
1.4
—
—
—
0
0
33
218
1.54
1.52
1.8
2.4
47.29
41.19
u/l
0.78
28
198
86
677
1.31
1.51
3.6
3.4
0.82
0.82
mmol/l
0.09
80
645
7
28
2.52
1.45
1.6
1.2
—
—
—
0
0
85
672
1.31
1.45
2.1
2.2
14.78
14.45
umol/l
0.15
78
614
44
606
0.71
1.44
3.2
2.8
0.86
0.71
ug/l
0.63
24
370
9
180
0.49
1.41
4.1
2.2
0.77
0.65
%
—
9
180
7
29
2.43
1.39
1.0
1.0
—
—
—
0
0
68
524
1.33
1.39
6.2
5.4
1.03
1.03
mmol/l
0.05
58
485
12
60
2.02
1.39
2.2
1.9
—
—
—
0
0
16
89
1.82
1.38
1.3
1.7
9904.30
15429.97
e6/l
—
10
70
5
17
2.96
1.36
1.4
1.2
—
—
—
0
0
29
427
0.66
1.36
1.9
1.7
—
—
—
0
0
10
47
2.15
1.34
1.2
1.7
—
—
—
0
0
9
42
2.16
1.34
1.3
1.2
—
—
—
0
0
9
43
2.11
1.30
1.3
1.3
—
—
—
0
0
28
411
0.67
1.30
1.9
2.1
34.86
34.81
u/l
0.00
22
349
8
34
2.37
1.29
1.1
1.1
—
—
—
0
0
6
135
0.44
1.28
1.3
1.5
—
—
—
0
0
17
99
1.74
1.28
1.9
1.7
—
—
—
0
0
39
280
1.42
1.24
1.3
1.3
226.47
246.06
miu/ml
0.10
20
144
134
1142
1.22
1.23
1.9
1.6
0.64
0.95
mg/l
2.08
88
855
10
49
2.06
1.22
1.1
1.0
—
—
—
0
0
5
19
2.64
1.22
1.0
1.5
—
—
—
0
0
5
19
2.64
1.22
1.2
1.2
9.20
12.05
u/l
—
5
19
10
187
0.53
1.20
4.0
2.3
1.67
1.36
%
—
10
187
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
26
2.32
1.19
1.7
1.2
—
—
—
0
0
272
2479
1.17
1.18
2.9
2.7
163.37
97.02
ug/l
0.63
243
2311
17
102
1.69
1.17
2.1
1.2
—
—
—
0
0
0
34
0.00
1.16
0.0
1.6
—
—
—
0
0
13
72
1.82
1.15
1.2
1.1
—
—
—
0
0
5
20
2.51
1.15
1.2
1.1
131.56
28.30
u/ml
—
5
20
5
20
2.51
1.15
5.0
2.0
—
—
—
0
0
23
151
1.54
1.13
1.3
1.1
—
—
—
0
0
7
30
2.35
1.12
1.3
1.7
—
—
—
0
0
19
120
1.60
1.09
3.7
1.3
411.63
425.96
mg/l
0.11
19
115
5
21
2.39
1.09
1.2
1.4
14.00
14.90
u/l
—
5
21
36
263
1.39
1.06
1.5
1.8
3.55
3.68
mg/l
0.05
28
187
12
67
1.81
1.05
1.2
1.7
—
—
—
0
0
9
46
1.97
1.04
4.1
2.2
—
—
—
0
0
58
459
1.29
1.02
1.2
1.2
160.90
149.57
iu/ml
0.06
18
184
50
388
1.31
1.02
2.9
4.4
3.67
32.78
ug/l
0.91
38
320
75
614
1.25
1.01
2.1
2.2
2.39
2.38
g/l
0.07
70
558
22
148
1.50
0.99
2.5
1.6
32.05
40.15
nmol/l
1.38
22
141
57
710
0.78
0.99
1.7
2.8
2.44
2.43
mmol/l
0.10
46
632
20
135
1.50
0.90
1.6
1.9
3.48
6.14
iu/l
—
8
45
9
152
0.59
0.89
1.0
1.2
—
—
—
0
0
9
153
0.58
0.89
1.0
1.2
—
—
—
0
0
9
155
0.57
0.89
1.9
3.6
19.11
1613.32
u/ml
—
9
132
8
42
1.92
0.89
1.6
1.4
1.25
1.05
promille
—
8
31
65
784
0.81
0.87
3.7
3.2
111.78
507.75
ng/l
1.54
39
520
8
47
1.71
0.81
1.0
1.3
—
—
—
0
0
8
48
1.68
0.79
1.3
1.6
—
—
—
0
0
14
90
1.57
0.78
1.1
1.1
—
—
—
0
0
6
34
1.77
0.76
1.0
1.1
—
—
—
0
0
16
232
0.68
0.76
1.4
1.5
—
—
—
0
0
41
511
0.79
0.74
2.9
2.7
14.14
7.90
umol/l
0.49
35
426
7
38
1.85
0.73
1.3
1.9
11.03
22.05
ug/l
—
7
38
17
118
1.45
0.70
1.2
1.2
—
—
—
0
0
41
505
0.80
0.68
1.3
1.5
—
—
—
0
0
73
626
1.19
0.67
2.2
2.0
28.93
29.29
s
0.20
68
608
8
50
1.61
0.61
1.5
1.3
21.88
21.83
nmol/l
—
8
44
11
163
0.67
0.60
4.5
3.3
51.24
49.11
%
0.11
11
163
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
72
823
0.86
0.57
3.4
3.8
25.80
21.38
%
1.09
27
352
5
87
0.57
0.56
1.2
1.1
—
—
—
0
0
11
73
1.52
0.56
1.4
1.2
—
—
—
0
0
36
294
1.24
0.55
2.2
2.9
67.22
67.05
g/l
0.04
31
273
115
1039
1.13
0.55
3.9
4.3
1.57
2.24
ug/l
1.21
98
937
6
39
1.54
0.53
1.2
1.2
71.50
77.31
umol/l
—
6
39
65
566
1.17
0.52
2.1
2.3
23.96
25.08
%
0.22
57
479
9
63
1.43
0.52
1.2
1.4
0.43
0.55
nmol/l
—
9
58
29
357
0.80
0.51
1.4
1.3
—
—
—
0
0
6
41
1.47
0.50
1.0
1.1
—
—
—
0
0
6
41
1.47
0.50
1.0
1.1
—
—
—
0
0
27
334
0.80
0.50
5.7
7.0
129.78
122.66
g/l
1.27
27
325
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
13
94
1.39
0.46
1.5
3.0
0.40
0.37
u/ml
—
6
50
8
120
0.66
0.46
1.1
1.4
0.16
0.38
nmol/l
—
8
102
5
31
1.62
0.43
1.8
1.2
172.56
167.45
pmol/l
—
5
31
6
95
0.63
0.42
1.8
1.8
—
—
—
0
0
8
57
1.41
0.42
1.1
1.1
—
—
—
0
0
13
96
1.36
0.42
2.4
1.7
—
—
—
0
0
8
59
1.36
0.41
1.1
1.1
—
—
—
0
0
8
59
1.36
0.41
1.5
1.2
—
—
—
0
0
8
59
1.36
0.41
1.3
1.6
—
—
—
0
0
0
18
0.00
0.40
0.0
3.3
—
—
—
0
0
6
42
1.43
0.35
1.0
1.1
—
—
—
0
0
6
42
1.43
0.35
1.0
1.1
—
—
—
0
0
6
42
1.43
0.35
1.0
1.1
—
—
—
0
0
20
241
0.82
0.32
1.6
2.0
—
—
—
0
0
26
304
0.85
0.31
2.6
2.6
22.95
51.36
u/ml
1.06
26
288
7
99
0.70
0.31
6.1
3.7
59.57
56.23
%
—
7
99
28
240
1.17
0.30
1.5
1.4
—
—
—
0
0
8
108
0.74
0.29
1.1
1.2
—
—
—
0
0
7
57
1.23
0.29
1.4
1.4
—
—
—
0
0
30
342
0.87
0.27
8.2
3.3
2.10
1.90
mmol/l
0.12
24
277
31
274
1.14
0.24
2.0
1.7
—
—
—
0
0
15
124
1.21
0.24
1.3
1.2
—
—
—
0
0
5
38
1.32
0.23
1.2
1.1
—
—
—
0
0
5
39
1.28
0.23
2.4
1.6
—
—
—
0
0
5
40
1.25
0.22
1.4
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
5.36
—
0
5
0
10
0.00
0.21
0.0
1.8
—
—
—
0
0
162
1684
0.95
0.21
3.1
3.2
30.42
31.13
u/l
0.14
157
1593
8
101
0.79
0.21
1.6
1.2
—
110.22
—
0
18
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
6
50
1.20
0.19
5.8
5.0
13.95
10.78
mg/l
—
6
45
6
51
1.18
0.19
1.0
1.1
—
—
—
0
0
30
272
1.11
0.17
1.2
1.4
—
—
—
0
0
30
272
1.11
0.17
1.2
1.4
—
—
—
0
0
30
272
1.11
0.17
1.2
1.4
—
—
—
0
0
13
110
1.19
0.17
3.5
3.7
—
2.19
—
0
14
65
612
1.07
0.17
1.5
1.6
—
—
—
0
0
30
273
1.10
0.16
1.2
1.4
—
—
—
0
0
8
70
1.14
0.16
1.3
1.1
—
—
—
0
0
7
90
0.78
0.14
3.1
1.8
13.14
13.10
%
—
7
90
38
403
0.94
0.10
5.0
6.5
0.09
0.84
mmol/l
0.27
28
314
5
44
1.14
0.10
1.2
1.7
0.83
1.05
g/l
—
5
44
5
62
0.80
0.08
1.2
1.0
—
—
—
0
0
6
75
0.80
0.07
1.8
1.4
—
—
—
0
0
8
77
1.04
0.07
1.0
1.4
—
—
—
0
0
35
334
1.05
0.07
2.1
2.6
73.45
71.81
ml/min/173m2
0.08
11
126
31
297
1.05
0.05
1.3
1.5
—
—
—
0
0
22
231
0.95
0.04
1.4
2.5
0.18
0.18
e6/l
0.01
22
223
33
342
0.96
0.04
1.6
1.4
—
—
—
0
0
12
128
0.94
0.02
3.5
2.0
—
—
—
0
0
28
287
0.97
0.01
1.3
1.6
319.04
290.28
mu/l
0.19
28
255
10
104
0.96
0.00
1.2
1.6
—
—
—
0
0
11
106
1.04
0.00
1.7
2.3
99.22
104.98
ug/min
—
6
63
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
2.7
—
0.50
—
0
6
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
60
1.00
-0.00
1.0
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_DYSHIDROSIS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_DYSHIDROSIS | 1.254 [0.92, 1.71] | 0.15 |
| Birth year | 0.999 [0.99, 1.01] | 0.788 |
During the follow-up period (1.1.1998 — 31.12.2019), 67 out of 1569 females with L12_DYSHIDROSIS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_DYSHIDROSIS | 1.603 [1.25, 2.06] | < 0.001 |
| Birth year | 0.985 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 93 out of 941 males with L12_DYSHIDROSIS died.
Mortality risk
Mortality risk for people of age
years, who have L12_DYSHIDROSIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.106% | 0.215% |
| 5 | 0.884% | 1.593% |
| 10 | 2.169% | 4.084% |
| 15 | 3.959% | 7.696% |
| 20 | 7.136% | 13.227% |
Relationships between endpoints
↥Index endpoint: L12_DYSHIDROSIS – Dyshidrosis [pompholyx]
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data